1	The	the	DT	_	4	det	_
2	health	health	NN	_	3	nn	_
3	care	care	NN	_	4	nn	_
4	sector	sector	NN	_	5	nsubj	5:A0
5	witnessed	witness	VBD	pb=witness.01	0	root	_
6	several	several	JJ	_	7	amod	_
7	collaborations	collaboration	NNS	_	5	dobj	5:A1
8	last	last	JJ	p2=IN	9	amod	_
9	week	week	NN	_	5	npadvmod	5:AM-TMP
10	,	,	,	_	5	punct	_
11	including	include	VBG	_	5	prep	_
12	a	a	DT	_	13	det	_
13	couple	couple	NN	_	11	pobj	14:A1=PPT
14	related	relate	VBN	p2=JJ|pb=relate.01	13	amod	_
15	to	to	IN	_	14	prep	14:A2=PPT
16	immuno	immuno	NN	p2=RB	18	hmod	_
17	-	-	HYPH	_	18	hyph	_
18	oncology	oncology	NN	_	15	pobj	_
19	.	.	.	_	5	punct	_

1	Another	another	DT	_	2	det	_
2	deal	deal	NN	_	4	nsubjpass	4:A1=PPT
3	was	be	VBD	_	4	auxpass	_
4	struck	strike	VBN	pb=strike.01	0	root	_
5	between	between	IN	_	4	prep	4:AM-LOC
6	Ligand	ligand	NNP	_	8	nn	_
7	Pharmaceuticals	pharmaceuticals	NNP	p2=NNPS	8	nn	_
8	Inc	inc	NNP	_	5	pobj	_
9	.	.	.	_	4	punct	_

1	(	(	-LRB-	_	2	punct	_
2	LGND	lgnd	NNP	p2=UH	0	root	_
3	)	)	-RRB-	_	2	punct	_
4	and	and	CC	_	2	cc	_
5	Omthera	omthera	NNP	_	6	nn	_
6	Pharmaceuticals	pharmaceuticals	NNP	p2=NNPS	2	conj	_
7	,	,	,	_	6	punct	_
8	Inc	inc	NNP	_	6	appos	_
9	.	.	.	_	2	punct	_

1	,	,	,	_	6	punct	_
2	a	a	DT	_	6	det	_
3	wholly	wholly	RB	_	5	hmod	_
4	-	-	HYPH	_	5	hyph	_
5	owned	own	VBN	_	6	amod	_
6	subsidiary	subsidiary	NN	_	0	root	_
7	of	of	IN	_	6	prep	_
8	AstraZeneca	astrazeneca	NNP	_	9	nn	_
9	plc	plc	NNP	p2=NN	7	pobj	_
10	(	(	-LRB-	_	9	punct	_
11	AZN	azn	NNP	_	9	appos	_
12	)	)	-RRB-	_	9	punct	_
13	.	.	.	_	6	punct	_

1	The	the	DT	_	2	det	_
2	companies	company	NNS	_	3	nsubj	3:A0=PAG
3	announced	announce	VBD	pb=announce.01	0	root	_
4	a	a	DT	_	8	det	_
5	licensing	licensing	NN	_	8	nn	_
6	and	and	CC	_	5	cc	_
7	research	research	NN	_	5	conj	_
8	deal	deal	NN	_	3	dobj	3:A1=PPT;13:AM-LOC
9	under	under	IN	_	13	prep	13:R-AM-LOC
10	which	which	WDT	_	9	pobj	_
11	they	they	PRP	_	13	nsubj	_
12	will	will	MD	_	13	aux	13:AM-MOD
13	develop	develop	VB	pb=develop.01	8	rcmod	_
14	novel	novel	JJ	p2=NN	15	amod	_
15	candidates	candidate	NNS	_	13	dobj	16:A0=PAG;13:A1=LOC
16	utilizing	utilize	VBG	pb=utilize.01	15	partmod	_
17	Ligand	ligand	NNP	_	21	poss	_
18	's	's	POS	_	17	possessive	_
19	LTP	ltp	NNP	p2=JJ	21	nn	_
20	technology	technology	NN	_	21	nn	_
21	platform	platform	NN	_	16	dobj	16:A1=PPT
22	for	for	IN	_	21	prep	_
23	the	the	DT	_	24	det	_
24	treatment	treatment	NN	_	22	pobj	_
25	of	of	IN	_	24	prep	_
26	dyslipidemia	dyslipidemia	NN	_	25	pobj	_
27	,	,	,	_	24	punct	_
28	including	include	VBG	_	24	prep	_
29	hypertriglyceridemia	hypertriglyceridemia	NN	_	28	pobj	_
30	.	.	.	_	3	punct	_

1	A	a	DT	p2=IN	9	det	_
2	recent	recent	JJ	_	9	amod	_
3	National	national	NNP	_	4	nn	_
4	Health	health	NNP	_	8	nn	_
5	and	and	CC	_	4	cc	_
6	Nutrition	nutrition	NNP	_	7	nn	_
7	Examination	examination	NNP	_	4	conj	_
8	Survey	survey	NNP	_	9	nn	_
9	analysis	analysis	NN	_	13	nsubj	13:A0=CAU
10	in	in	IN	_	9	prep	_
11	the	the	DT	_	12	det	_
12	U.S.	u.s.	NNP	_	10	pobj	_
13	showed	show	VBD	pb=show.01	0	root	_
14	that	that	IN	_	24	complm	_
15	the	the	DT	_	16	det	_
16	percentage	percentage	NN	_	24	nsubj	24:A1
17	of	of	IN	_	16	prep	_
18	patients	patient	NNS	_	17	pobj	19:A0=PPT
19	suffering	suffer	VBG	pb=suffer.01	18	partmod	_
20	from	from	IN	_	19	prep	19:A1=PAG
21	severe	severe	JJ	_	22	amod	_
22	hypertriglyceridemia	hypertriglyceridemia	NN	_	20	pobj	_
23	is	be	VBZ	_	24	aux	_
24	rising	rise	VBG	pb=rise.01	13	ccomp	13:A1=PPT
25	sharply	sharply	RB	_	24	advmod	24:A2=EXT
26	with	with	IN	_	24	prep	_
27	rise	rise	NN	_	26	pobj	_
28	in	in	IN	_	27	prep	_
29	obesity	obesity	NN	_	28	pobj	_
30	.	.	.	_	13	punct	_

1	Ligand	ligand	NNP	p2=JJR	3	nsubj	3:A0=PAG
2	will	will	MD	_	3	aux	3:AM-MOD
3	receive	receive	VB	pb=receive.01	0	root	_
4	up	up	IN	_	8	quantmod	_
5	to	to	TO	_	8	quantmod	_
6	$	$	$	_	8	quantmod	_
7	44.5	0	CD	_	8	number	_
8	million	#crd#	CD	_	3	dobj	3:A1=PPT
9	from	from	IN	_	3	prep	3:A2=DIR
10	AstraZeneca	astrazeneca	NNP	_	9	pobj	_
11	on	on	IN	_	3	prep	3:AM-TMP
12	the	the	DT	_	13	det	_
13	achievement	achievement	NN	_	11	pobj	_
14	of	of	IN	_	13	prep	_
15	specific	specific	JJ	_	16	amod	_
16	milestones	milestone	NNS	_	14	pobj	_
17	.	.	.	_	3	punct	_

1	Additionally	additionally	RB	_	5	advmod	5:AM-DIS
2	,	,	,	_	5	punct	_
3	Ligand	ligand	NNP	_	5	nsubj	5:A0=PAG
4	will	will	MD	_	5	aux	5:AM-MOD
5	receive	receive	VB	pb=receive.01	0	root	_
6	tiered	tiered	VBN	p2=JJ|pb=tiered.01	10	amod	_
7	mid-to-high	mid-to-high	JJ	p2=VB	10	amod	_
8	single	single	JJ	_	9	amod	_
9	digit	digit	NN	_	10	nn	_
10	royalties	royalty	NNS	_	5	dobj	5:A1=PPT;6:A1
11	on	on	IN	_	5	prep	_
12	net	net	JJ	_	13	amod	_
13	sales	sale	NNS	_	11	pobj	_
14	of	of	IN	_	13	prep	_
15	the	the	DT	_	16	det	_
16	products	product	NNS	_	14	pobj	_
17	to	to	TO	_	19	aux	_
18	be	be	VB	_	19	auxpass	_
19	developed	develop	VBN	pb=develop.02	13	infmod	_
20	.	.	.	_	5	punct	_

1	Moreover	moreover	RB	_	5	advmod	5:AM-DIS
2	,	,	,	_	5	punct	_
3	Omthera	omthera	NNP	_	5	nsubj	5:A0=PPT
4	will	will	MD	_	5	aux	5:AM-MOD
5	bear	bear	VB	pb=bear.01	0	root	_
6	the	the	DT	_	8	det	_
7	total	total	JJ	_	8	amod	_
8	cost	cost	NN	_	5	dobj	5:A1=PAG
9	of	of	IN	_	8	prep	_
10	research	research	NN	_	9	pobj	_
11	and	and	CC	_	10	cc	_
12	development	development	NN	_	10	conj	_
13	as	as	RB	_	15	advmod	_
14	well	well	RB	_	15	advmod	_
15	as	as	IN	_	10	cc	_
16	commercialization	commercialization	NN	_	10	conj	_
17	of	of	IN	_	16	prep	_
18	any	any	DT	_	19	det	_
19	product	product	NN	_	17	pobj	20:A1=PRD
20	developed	develop	VBN	pb=develop.02	19	partmod	_
21	under	under	IN	_	20	prep	20:AM-LOC
22	this	this	DT	_	23	det	_
23	collaboration	collaboration	NN	_	21	pobj	_
24	.	.	.	_	5	punct	_

1	We	we	PRP	_	2	nsubj	2:A1=PPT
2	are	be	VBP	pb=be.01	0	root	_
3	positive	positive	JJ	_	2	acomp	2:A2=PRD
4	on	on	IN	_	3	prep	_
5	the	the	DT	_	6	det	_
6	agreement	agreement	NN	_	4	pobj	_
7	between	between	IN	_	6	prep	_
8	Ligand	ligand	NNP	_	7	pobj	_
9	and	and	CC	_	8	cc	_
10	AstraZeneca	astrazeneca	NNP	_	8	conj	_
11	.	.	.	_	2	punct	_

1	The	the	DT	_	2	det	_
2	agreement	agreement	NN	_	4	nsubj	4:A1=PPT
3	should	should	MD	_	4	aux	4:AM-MOD
4	be	be	VB	pb=be.01	0	root	_
5	beneficial	beneficial	JJ	_	4	acomp	4:A2=PRD
6	for	for	IN	_	5	prep	_
7	Ligand	ligand	NNP	p2=NN	6	pobj	_
8	since	since	IN	_	11	mark	_
9	it	it	PRP	_	11	nsubj	11:A0=PAG
10	is	be	VBZ	_	11	aux	_
11	gaining	gain	VBG	pb=gain.02	4	advcl	4:AM-TMP
12	a	a	DT	_	14	det	_
13	strong	strong	JJ	_	14	amod	_
14	partner	partner	NN	_	11	dobj	11:A1=PPT
15	in	in	IN	_	14	prep	_
16	the	the	DT	_	17	det	_
17	form	form	NN	_	15	pobj	_
18	of	of	IN	_	17	prep	_
19	AstraZeneca	astrazeneca	NNP	_	18	pobj	_
20	.	.	.	_	4	punct	_

1	AstraZeneca	astrazeneca	NNP	_	3	poss	_
2	's	's	POS	_	1	possessive	_
3	competency	competency	NN	_	23	nsubj	10:A0=PAG;23:A0=PAG
4	in	in	IN	_	3	prep	_
5	molecule	molecule	NN	_	6	nn	_
6	discovery	discovery	NN	_	4	pobj	_
7	,	,	,	_	6	punct	_
8	design	design	NN	_	6	conj	_
9	and	and	CC	_	8	cc	_
10	targeting	target	VBG	p2=NN|pb=target.01	8	conj	_
11	combined	combine	VBN	pb=combine.01	6	partmod	_
12	with	with	IN	_	11	prep	11:A2=PPT
13	Omthera	omthera	NNP	_	15	poss	_
14	's	's	POS	_	13	possessive	_
15	proficiency	proficiency	NN	_	12	pobj	_
16	in	in	IN	_	15	prep	_
17	the	the	DT	_	18	det	_
18	field	field	NN	_	16	pobj	_
19	of	of	IN	_	18	prep	_
20	lipid	lipid	JJ	p2=NN	21	amod	_
21	disorders	disorder	NNS	_	19	pobj	_
22	will	will	MD	_	23	aux	23:AM-MOD
23	strengthen	strengthen	VB	pb=strengthen.01	0	root	_
24	Ligand	ligand	NNP	_	27	poss	_
25	's	's	POS	_	24	possessive	_
26	development	development	NN	_	27	nn	_
27	efforts	effort	NNS	_	23	dobj	23:A1=PPT
28	for	for	IN	_	27	prep	_
29	the	the	DT	_	30	det	_
30	treatment	treatment	NN	_	28	pobj	_
31	of	of	IN	_	30	prep	_
32	dyslipidemia	dyslipidemia	NN	_	34	hmod	_
33	-	-	HYPH	_	34	hyph	_
34	related	relate	VBN	_	35	amod	_
35	diseases	disease	NNS	_	31	pobj	_
36	.	.	.	_	23	punct	_

1	Moreover	moreover	RB	_	8	advmod	8:AM-DIS
2	,	,	,	_	8	punct	_
3	the	the	DT	_	4	det	_
4	terms	term	NNS	_	8	nsubj	8:A0=PAG
5	of	of	IN	_	4	prep	_
6	the	the	DT	_	7	det	_
7	deal	deal	NN	_	5	pobj	_
8	look	look	VBP	p2=VB|pb=look.02	22	ccomp	_
9	favorable	favorable	JJ	_	8	acomp	8:A1=PPT
10	−	−	,	p2=PDT	22	punct	_
11	all	all	DT	_	12	det	_
12	costs	cost	NNS	_	22	nsubjpass	13:A1=PPT;22:A1=PPT
13	related	relate	VBN	p2=JJ|pb=relate.01	12	partmod	_
14	to	to	IN	_	13	prep	13:A2=PPT
15	development	development	NN	_	14	pobj	_
16	of	of	IN	_	15	prep	_
17	the	the	DT	_	19	det	_
18	novel	novel	JJ	p2=NN	19	amod	_
19	candidates	candidate	NNS	_	16	pobj	_
20	will	will	MD	_	22	aux	22:AM-MOD
21	be	be	VB	_	22	auxpass	_
22	borne	bear	VBN	pb=bear.02	0	root	_
23	by	by	IN	_	22	agent	22:A0=PAG
24	Omthera	omthera	NNP	p2=NN	23	pobj	_
25	.	.	.	_	22	punct	_

1	Some	some	DT	_	2	det	_
2	drugs	drug	NNS	_	10	nsubj	3:A1=PPT;10:A2=GOL
3	approved	approve	VBN	p2=VBD|pb=approve.01	2	partmod	_
4	for	for	IN	_	3	prep	3:A2=PRD
5	the	the	DT	_	6	det	_
6	treatment	treatment	NN	_	4	pobj	_
7	of	of	IN	_	6	prep	_
8	severe	severe	JJ	_	9	amod	_
9	hypertriglyceridemia	hypertriglyceridemia	NN	_	7	pobj	_
10	include	include	VBP	pb=include.01	0	root	_
11	AstraZeneca	astrazeneca	NNP	_	13	poss	_
12	's	's	POS	_	11	possessive	_
13	Epanova	epanova	NNP	_	10	dobj	10:A1=PPT
14	and	and	CC	_	13	cc	_
15	Amarin	amarin	NNP	_	20	poss	_
16	's	's	POS	_	15	possessive	_
17	(	(	-LRB-	_	20	punct	_
18	AMRN	amrn	NNP	p2=NN	20	nn	_
19	)	)	-RRB-	_	20	punct	_
20	Vascepa	vascepa	NNP	_	13	conj	_
21	.	.	.	_	10	punct	_

1	Ligand	ligand	NNP	p2=NN	2	nsubj	2:A0=PAG
2	carries	carry	VBZ	pb=carry.01	0	root	_
3	a	a	DT	_	9	det	_
4	Zacks	zacks	NNP	p2=NNPS	5	nn	_
5	Rank	rank	NNP	_	9	npadvmod	_
6	#	#	$	p2=NN	7	nmod	_
7	3	0	CD	_	5	num	_
8	(	(	-LRB-	_	9	punct	_
9	Hold	hold	VB	p2=NNP	2	dobj	_
10	)	)	-RRB-	_	9	punct	_
11	.	.	.	_	2	punct	_

1	Ligand	ligand	NNP	p2=JJ	3	nsubj	3:A0=PAG;10:A1=PPT
2	has	have	VBZ	_	3	aux	_
3	partnered	partner	VBN	p2=JJ|pb=partner.01	0	root	_
4	programs	program	NNS	_	3	dobj	3:A1=COM
5	with	with	IN	_	3	prep	_
6	several	several	JJ	_	7	amod	_
7	companies	company	NNS	_	5	pobj	_
8	and	and	CC	_	3	cc	_
9	is	be	VBZ	_	10	aux	_
10	awaiting	await	VBG	pb=await.01	3	conj	_
11	several	several	JJ	_	13	amod	_
12	regulatory	regulatory	JJ	_	13	amod	_
13	events	event	NNS	_	10	dobj	10:A2=PPT
14	.	.	.	_	3	punct	_

1	We	we	PRP	_	2	nsubj	2:A0
2	expect	expect	VBP	pb=expect.01	0	root	_
3	2014	0	CD	_	5	nsubj	5:A1=PPT
4	to	to	TO	_	5	aux	_
5	be	be	VB	pb=be.01	2	ccomp	2:A1=PPT
6	a	a	DT	_	7	det	_
7	catalyst	catalyst	NN	_	5	attr	5:A2=PRD
8	rich	rich	JJ	_	9	amod	_
9	year	year	NN	_	5	npadvmod	5:AM-TMP
10	for	for	IN	_	7	prep	_
11	Ligand	ligand	NNP	p2=NN	10	pobj	_
12	.	.	.	_	2	punct	_

1	A	a	DT	_	5	det	_
2	better	good	JJR	p2=RBR	4	hmod	_
3	-	-	HYPH	_	4	hyph	_
4	ranked	rank	VBN	p2=VBD|pb=rank.01	5	amod	_
5	stock	stock	NN	_	10	nsubj	4:A1=PPT;10:A1=PPT
6	in	in	IN	_	5	prep	_
7	the	the	DT	_	9	det	_
8	biotech	biotech	JJ	p2=NN	9	amod	_
9	sector	sector	NN	_	6	pobj	_
10	is	be	VBZ	pb=be.01	0	root	_
11	Gilead	gilead	NNP	_	13	nn	_
12	Sciences	science	NNPS	_	13	nn	_
13	Inc	inc	NNP	_	10	attr	10:A2=PRD
14	.	.	.	_	10	punct	_

1	(	(	-LRB-	_	4	punct	_
2	GILD	gild	NNP	p2=NN	4	nsubj	4:A0=PAG
3	)	)	-RRB-	_	2	punct	_
4	carrying	carry	VBG	pb=carry.01	0	root	_
5	a	a	DT	_	7	det	_
6	Zacks	zacks	NNP	_	7	nn	_
7	Rank	rank	NNP	_	4	dobj	4:A1=PPT
8	#	#	$	p2=NN	9	nmod	_
9	1	0	CD	_	7	num	_
10	(	(	-LRB-	_	7	punct	_
11	Strong	strong	JJ	p2=NNP	12	amod	_
12	Buy	buy	NNP	p2=NN	8	appos	_
13	)	)	-RRB-	_	4	punct	_
14	.	.	.	_	4	punct	_

